相关实验视频
Updated: Jun 24, 2025

11:36
Glycan Node Analysis: A Bottom-up Approach to Glycomics
Published on: May 22, 2016
10.4K
糖基化编辑:在精密瘤学中,这是一个创新的治疗机会
Xiao-Feng Dai1, Yi-Xuan Yang2, Bo-Zhi Yang2
1National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China. xiaofengteam@163.com.
Molecular and cellular biochemistry
|June 11, 2024
概括
与细胞氧化还原状态相关的改变糖基化,提供了新的癌症诊断和治疗策略. 冷大气等离子体 (CAP) 可能通过编辑糖化,提供新的癌症控制.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 生物物理学的生物物理.
背景情况:
- 癌症仍然是一个重大的全球健康挑战.
- 改变的糖化模式越来越多地被认为是各种健康状况的指标,包括癌症.
- 了解糖代谢在癌症中的作用对于开发新疗法至关重要.
研究的目的:
- 审查参与糖系化过程中的机制和酶.
- 探索当前在癌症诊断和治疗中使用糖化酶的应用.
- 为了确定糖化和细胞氧化还原状态之间的联系,用于新的治疗方法.
主要方法:
- 关于糖化机制,酶和癌症应用的文献综述.
- 分析糖化和细胞氧化还原平衡之间的联系.
- 冷大气等离子体 (CAP) 作为糖化编辑的工具的建议.
主要成果:
- 在癌症中,葡萄糖酶化概况发生变化,可以作为诊断和治疗点.
- 糖化和细胞氧化还原状态之间存在着关键的联系.
- 冷大气等离子体 (CAP) 显示出调节糖化酶的潜力.
结论:
- 糖基化编辑为癌症控制提供了一个有希望的途径.
- 冷大气等离子体 (CAP) 可能是精密瘤学的宝贵工具.
- 对糖化和氧化还原调节的进一步研究可能会产生新的癌症疗法.
相关概念视频
Protein Glycosylation
6.9K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
6.9K
RNA Editing
9.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.0K
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K

